Media coverage about Edap Tms (NASDAQ:EDAP) has trended somewhat negative recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Edap Tms earned a news sentiment score of -0.01 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 45.8262341523699 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
EDAP has been the subject of a number of analyst reports. Zacks Investment Research raised Edap Tms from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Tuesday, November 28th. HC Wainwright reissued a “buy” rating and issued a $6.50 price target on shares of Edap Tms in a research report on Wednesday, November 22nd. Finally, ValuEngine raised Edap Tms from a “sell” rating to a “hold” rating in a research report on Friday, October 6th.
Shares of Edap Tms (NASDAQ EDAP) opened at $2.69 on Tuesday. The company has a market capitalization of $80.90, a price-to-earnings ratio of -33.62 and a beta of 1.02. Edap Tms has a 12-month low of $2.25 and a 12-month high of $3.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.96 and a quick ratio of 2.35.
About Edap Tms
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.